Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls
With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.
You may also be interested in...
Medicare Price Negotiation: Sponsors Will Have A Say, But Likely Not Sway As Timetable Comes Into Focus
CMS details when it will release information and receive public comments in the lead-up to publishing the initial list of drugs to be negotiated this fall.
Novartis’ Blockbuster Hopeful Leqvio Faces Perils Of Medicare’s Pricing Policy On Small Molecules
Medicare’s pending price negotiation program could impact the longevity of the Part B cholesterol drug Leqvio. Novartis CEO Vas Narasimhan notes the upcoming redesign of the Part D benefit could boost pricing pressure on Kisqali.
PBM Transparency Act Advances In Senate And It’s A Far Cry From The Rebate Rule
Bill aims to lower patient costs in part by engaging the US Federal Trade Commission to shed light on pharmacy benefit manager transactions with health plans, manufacturers and pharmacies.